Zymeworks removes CFO; Gilead extends Nurix deal
2024-04-02
高管变更IPO
Plus, news about Onconova Therapeutics, Trawsfynydd Therapeutics, Nocion Therapeutics, Ginkgo Bioworks and Modulus Therapeutics:
Zymeworks ousts CFO:
The biotech
disclosed
Monday that it had removed CFO Christopher Astle on March 31, though did not provide a reason in an SEC filing. President and CEO Kenneth Galbraith is serving as interim CFO until the company finds a replacement. “Following careful consideration, and in the interest of our commitment to continuing our growth and success, the decision was made to initiate a search for a new CFO who possesses the specific experience, expertise and vision to drive our business strategies forward effectively,” a spokesperson wrote to
Endpoints
in an email. The company’s shares
$ZYME
fell about 4% on Tuesday.
— Lei Lei Wu
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-靶点
-药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。